The Centers for Medicare & Medicaid Services (CMS) recently issued a final national coverage decision memo for preexposure prophylaxis (PrEP) antiretroviral drugs to prevent HIV infection. As of Sept. 30, Medicare Part B covers Food and Drug Administration (FDA)-approved PrEP and related services for individuals at increased risk of getting HIV with no cost-sharing (e.g., deductibles or co-pays). The physician or health care practitioner who assesses the patient’s history determines whether they’re at increased risk. Medicare previously covered FDA-approved oral or injectable HIV PrEP drugs under Medicare Part D.
If you’re assessing your patients for PrEP to prevent HIV, or they’re already using it, Medicare Part B now covers the following as additional preventive services:
Submit claims to your Medicare administrative contractor for the other covered services related to PrEP for HIV, such as counseling, laboratory and point-of-care screening tests, administration of an injectable HIV PrEP drug, and for the injectable HIV PrEP drug if you purchase it. Use the following billing and payment codes:
Multiple diagnosis codes may be appropriate when you’re billing for PrEP, including the following:
In a separate action that also affects PrEP coverage, the U.S. Departments of Labor, Health and Human Services, and Treasury issued a set of frequently asked questions (FAQs) on Oct. 21 explaining key aspects of the Affordable Care Act and Women’s Health and Cancer Rights Act. The FAQs offer specific guidance for private health plans and insurers to ensure adherence to current health care regulations, including how plans must cover preventive services like PrEP following updated recommendations.
Under the federal guidance, most private plans will have to cover without cost-sharing any services that the U.S. Preventive Services Task Force (USPSTF) has given an “A” or “B” grade. This includes PrEP, for which USPSTF has assigned an “A” grade for sexually active adults and adolescents who weigh at least 77 pounds, do not already have HIV, and are at increased risk for acquiring HIV. Most private plans that begin on or after Aug. 31, 2024, must therefore cover oral and injectable PrEP, as well as baseline and monitoring services, with no deductibles or co-pays. They also may not use medical management techniques to steer individuals who have been prescribed PrEP toward one of the three FDA-approved formulations over another.
The federal guidance encourages clinicians and coders to use modifier 33 to denote when preventive services were provided in accordance with “A” or “B” USPSTF recommendations.
— Kent Moore, AAFP Senior Manager, Payment Strategies
Posted on Oct. 25, 2024
Disclaimer: The opinions and views expressed here are those of the authors and do not necessarily represent or reflect the opinions and views of the American Academy of Family Physicians. This blog is not intended to provide medical, financial, or legal advice. Some payers may not agree with the advice given. This is not a substitute for current CPT and ICD-9 manuals and payer policies. All comments are moderated and will be removed if they violate our Terms of Use.